Gismo Therapeutics Inc.

Lexington, KY

UEI
SY29WJMD4E85
CAGE
6GS16
Primary NAICS
Not on record
SAM.gov registration
Active through

Company facts

Self-certified in SAM.gov
  • For Profit Organization
Entity structure
Corporate Entity (Not Tax Exempt)
SAM.gov registration date
Physical address
145 Graham Ave, Lexington, KY 40508, USA
Website
gismotherapeutics.com
Founded
2011
Employees
1-10
Estimated annual revenue
$0-$1M
Industry
  1. Health Care
  2. Pharmaceuticals, Biotechnology & Life Sciences
  3. Biotechnology
SIC code
28 Chemical & Allied Products
Profiles

Registration and certifications come from SAM.gov and the SBA; company details from public web sources. Updated .

Grant awards

Award Agency Obligated Awarded
A novel therapeutic approach for targeting TDP-43 in ALS W81XWH2210379 Defense Health Agency $1,236,880
Glycosaminoglycan-interacting small molecule (gismo) as alzheimer's therapeutics R44AG056231 National Institute on Aging (NIH) $5,839,384
Glycosaminoglycan-interacting small molecule (gismo) as parkinson's therapeutic R43NS097105 National Institute of Neurological Disorders and Stroke (NIH) $384,126
Glycosaminoglycan-cytokine inhibitors for arthritis therapy R43AR068137 National Institutes of Health $224,997
Glycosaminoglycan interacting small molecules (gismo) as novel ad therapeutics R43AG044924 National Institutes of Health $197,137

Quick answers

Is Gismo Therapeutics Inc. registered in SAM.gov?

Yes. Gismo Therapeutics Inc.'s SAM.gov registration is active through September 16, 2027.

What is Gismo Therapeutics Inc.'s most recent federal award?

Gismo Therapeutics Inc.'s most recent federal grant award is A novel therapeutic approach for targeting TDP-43 in ALS (W81XWH2210379), from Defense Health Agency, on June 15, 2022.

On GovTribe

See Gismo Therapeutics Inc.'s full federal record

  • Federal grant awards
  • Funding analysis by agency, NAICS and set-aside
  • Similar vendors
Try for free Login